Embed Size (px)
Citation preview
ABC Life Sciencestargeted therapy for kidney disease
Paige Yellen, PhDFounder & CEO
Winners of Tri-Institutional Bench to Bedside Pitch Day-November 2015
2016
There are no effective therapies to treat or cure kidney disease
Chronic Kidney Disease (CKD)
20M/year (1/10 adults)
2. Dialysis
3. Kidney Transplant
American Society of Nephrology January 2016
Acute Kidney Injury (AKI)
1.2M/year
Renal Cell Carcinoma
62K/year
Standard of Care
Polycystic Kidney Disease (PKD)
600K/year
1. Supportive treatments
$92B market2016
Targeted Drug Delivery Platform for the Treatment of Kidney Diseases
Williams et al., Nano Letters 2015, 15, 2358−2364
Provisional Patent, Memorial Sloan Kettering Cancer Center (MSKCC), 2015
Platform Products to Optimize Kidney Treatment
ABC Life Sciences
Product FCollaborate with Device Company to validateefficacy of measuring riskof kidney disease(s)
Products B,C,DCollaborate with PharmaCompanies to improveefficacy of small molecule inhibitors to treat AKI, CKD, RCC
1st Product (A)-POCPrevent cisplatin-induced acute kidney injuryAnimal models
Product ECollaborate with Biotech Company to improve the safety and efficacy of their proprietary compound(s)
Internal development
External development
Scale-up, IND, Clinical Trials
Competitive Positioning
Efficacy
Few
er s
ide
effec
ts
ABC Life Sciencesnanoparticle
Acute Kidney Injury1st POC
pre-clinical
Dialysis(Standard of Care)
Market size
CatalentOptishell
CKDpre-clinical
Quark-siRNAP53
Acute Kidney InjuryPhase II
Phase IIA $30-35M Exit
Operations
1st Indication:prevent AKIin cisplatin-induced AKIwith generic drug(rodent models)
License IP(MSKCC)
Milestone #21st POC, Product 2
Milestone #3 IND
Sell to pharmacompany
Milestone #4Safety
Phase I $5M
CRO: GLP ToxicologyGMP
Milestone #52nd POC, Product
1
2018 2020 2022Preclinical
$2-4M
2016 2017
Test, select compounds for AKICollaborate with pharma/biotech company
Milestone #11st POC, Product 1
20212019
Scale-up
InternalDevelopment
External Development
ABC Life Sciences Team
Dan Heller, PhDInventor, MSKCCScientific Advisor
Edgar Jaimes, MDChief of Nephrology, MSKCC
Scientific Advisor
Paige Yellen, PhDFounder & CEO
Ryan Williams, PhDCo-inventor, MSKCCScientific Advisor
• Former post-doctoral fellow at Memorial Sloan Kettering Cancer Center (MSKCC)
• Expertise in signal transduction pathway and small molecule inhibitors
• Associate Professor, cancer nanomedicine lab
• Development of nanoscale targeted therapies and diagnostics
• published extensively on development and application of nanomedicines
• Physician scientist who has made important contributions to our understanding of pathogenesis of renal injury
• Participated in several clinical trials testing strategies for treatment of different types of kidney diseases
• Bachelor’s Degree in Biology; Ph.D. in Pharmaceutical and
Pharmacological Sciences• Research and development of
core technology
